<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208618">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00372190</url>
  </required_header>
  <id_info>
    <org_study_id>P0609</org_study_id>
    <nct_id>NCT00372190</nct_id>
  </id_info>
  <brief_title>Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse.</brief_title>
  <official_title>A Prospective and Comparative Study of the Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Pelvic organ prolapse is a common problem. A lot of women have surgery for prolapse. The
      recurrence rate op pelvic organ prolapse after surgical treatment is high. Placement of a
      mesh aims at reducing the recurrence rate, but mesh implants can cause complications.

      This study is designed to determine the effectiveness of one type of mesh (tensionfree
      vaginal mesh; Prolift), compared with the standard prolapse surgery. A secondary objective
      is to track the complications of both procedures.

      Patients with recurrent prolapse after surgery can participate in this study. A total of 194
      women will be included. At random 97 patients undergo a standard prolapse operation and 97
      patients undergo an operation with the mesh. Evaluation will take place during surgery, at
      the postoperative visit after six weeks, and after six months and twelve months. Quality of
      life, degree of vaginal prolapse, subjective effectiveness, safety and incidence of
      complications will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolapse by POPQ, at entry, after 6 months, after 12 months</measure>
    <time_frame>at entry, 6 months and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications during the procedure, after 6 weeks, after 6 months, after 12 months</measure>
    <time_frame>during procedure, after 6 weeks, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by standardised questionnaire, at entry, after 6 months, after 12 months</measure>
    <time_frame>at entry, after 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prolapse complaints by standardised questionnaires</measure>
    <time_frame>at entry, after 6 weeks, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tensionfree vaginal mesh (Prolift)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>classic vaginal prolapse surgery (fascia plication)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tensionfree vaginal mesh (Prolift)</intervention_name>
    <description>surgery with Prolift mesh</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>classic vaginal prolapse surgery (fascia plication)</intervention_name>
    <description>classic surgery, fascia plication</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent anterior and/or posterior prolapse POP-Q stage 2 or more

          -  patient has agreed to undergo implantation of TVM (prolift) or fascial plication

          -  patient is willing to return for follow-up evaluation at 6 weeks, 6 months and 12
             months

          -  patient is willing to complete quality of life questionnaires at 6 and 12 months

        Exclusion Criteria:

          -  patient is or wants to become pregnant

          -  patient has had previous synthetic mesh procedure (a previous mid-urethral sling
             procedure is NOT an exclusion criterion)

          -  patient has current urinary tract or vaginal infections

          -  patient has a blood coagulation disorder

          -  patient has a compromised immune system or any other condition that would compromise
             healing

          -  patient has renal insufficiency and/or upper urinary tract obstruction

          -  patient is unwilling or unable to return for evaluation

          -  patient has had previous irradiation

          -  patient has any malignancy

          -  patient has large ovarian cysts of large myoma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariella ij Withagen, Drs.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St Radboud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariella ij Withagen, Drs.</last_name>
    <phone>0031243614792</phone>
    <email>m.withagen@obgyn.umcn.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark e Vierhout, Prof. Dr.</last_name>
    <phone>0031243614728</phone>
    <email>m.vierhout@obgyn.umcn.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gelre ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Spaans, dr.</last_name>
      <email>w.spaans@gelre.nl</email>
    </contact>
    <investigator>
      <last_name>W. Spaans, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slysis Zorggroep, location Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A L. Milani, Drs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E. Everhardt, dr.</last_name>
    </contact>
    <investigator>
      <last_name>E Everhardt, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I van der Wijk, drs</last_name>
    </contact>
    <investigator>
      <last_name>I van der Wijk, drs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>H L Schagen van Leeuwen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M IJ Withagen, Drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ikazia</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J de Leeuw, dr</last_name>
    </contact>
    <investigator>
      <last_name>J de Leeuw, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Refaja</name>
      <address>
        <city>Stadskanaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H de Wet</last_name>
      <email>dewet@refaja.nl</email>
    </contact>
    <investigator>
      <last_name>H. de Wet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>H AM Vervest, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Twee Steden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A MW Broekman, Drs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.F.P. Mulder, drs</last_name>
    </contact>
    <investigator>
      <last_name>A.F.P. Mulder, drs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J den Boon, dr</last_name>
    </contact>
    <investigator>
      <last_name>J den Boon, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <lastchanged_date>June 6, 2008</lastchanged_date>
  <firstreceived_date>September 5, 2006</firstreceived_date>
  <responsible_party>
    <name_title>M.I.J. Withagen</name_title>
    <organization>Radboud University, department of obstetrics and gynaecology</organization>
  </responsible_party>
  <keyword>Pelvic organ prolapse</keyword>
  <keyword>recurrence</keyword>
  <keyword>mesh</keyword>
  <keyword>complications</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
